Your browser doesn't support javascript.
loading
Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages.
Manara, Maria Cristina; Manferdini, Cristina; Cristalli, Camilla; Carrabotta, Marianna; Santi, Spartaco; De Feo, Alessandra; Caldoni, Giulia; Pasello, Michela; Landuzzi, Lorena; Lollini, Pier-Luigi; Salamanna, Francesca; Dominici, Sabrina; Fiori, Valentina; Magnani, Mauro; Lisignoli, Gina; Scotlandi, Katia.
Afiliação
  • Manara MC; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Manferdini C; Laboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Cristalli C; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Carrabotta M; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Santi S; CNR Institute of Molecular Genetics "Luigi Luca Cavalli-Sforza", Unit of Bologna, Bologna, Italy.
  • De Feo A; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Caldoni G; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Pasello M; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Landuzzi L; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Lollini PL; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Salamanna F; Laboratory of Immunology and Biology of Metastasis, Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
  • Dominici S; Surgical Sciences and Technologies, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
  • Fiori V; Diatheva Srl, Cartoceto, Italy.
  • Magnani M; Diatheva Srl, Cartoceto, Italy.
  • Lisignoli G; Department of Biomolecular Sciences, University of Urbino "Carlo Bo", Urbino, Italy.
  • Scotlandi K; Laboratorio di Immunoreumatologia e Rigenerazione Tissutale, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Cancer Immunol Res ; 12(2): 247-260, 2024 02 02.
Article em En | MEDLINE | ID: mdl-38051221
ABSTRACT
Ewing sarcoma (EWS) is the second most common pediatric bone tumor. The EWS tumor microenvironment is largely recognized as immune-cold, with macrophages being the most abundant immune cells and their presence associated with worse patient prognosis. Expression of CD99 is a hallmark of EWS cells, and its targeting induces inhibition of EWS tumor growth through a poorly understood mechanism. In this study, we analyzed CD99 expression and functions on macrophages and investigated whether the concomitant targeting of CD99 on both tumor and macrophages could explain the inhibitory effect of this approach against EWS. Targeting CD99 on EWS cells downregulated expression of the "don't eat-me" CD47 molecule but increased levels of the "eat-me" phosphatidyl serine and calreticulin molecules on the outer leaflet of the tumor cell membrane, triggering phagocytosis and digestion of EWS cells by macrophages. In addition, CD99 ligation induced reprogramming of undifferentiated M0 macrophages and M2-like macrophages toward the inflammatory M1-like phenotype. These events resulted in the inhibition of EWS tumor growth. Thus, this study reveals what we believe to be a previously unrecognized function of CD99, which engenders a virtuous circle that delivers intrinsic cell death signals to EWS cells, favors tumor cell phagocytosis by macrophages, and promotes the expression of various molecules and cytokines, which are pro-inflammatory and usually associated with tumor regression. This raises the possibility that CD99 may be involved in boosting the antitumor activity of macrophages.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Sarcoma de Ewing / Neoplasias Ósseas Idioma: En Ano de publicação: 2024 Tipo de documento: Article